Filana Therapeutics Q2 EPS $(0.18) Beats $(0.23) Estimate
Filana Therapeutics Inc FLNA
$1.01
▲ +5.21%
(+$0.05)
⬆️ Above Yest. High
🗓️ Earnings Next Week
Open
$0.96
Prev Close
$0.96
Day Range
$0.94 – $1.02
52W Range
$0.86 – $2.27
Market Cap
$48.79M
Beta
1.67
EPS (TTM)
$-1.61
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2000-07-14 |
| Shares Out. | 48,310,000 |
| Website | cassavasciences.com/ ↗ |
| Phone | 13026587581 |
| Employees | 20 |
| Net Income | -$8.6M |
| Free Cash Flow | -$29.3M |
| Total Assets | $103.9M |
| Total Liabilities | $40.3M |
| Equity | $63.6M |
About Filana Therapeutics Inc
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
Filana Therapeutics Inc is a publicly traded company under the ticker symbol FLNA on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-03-01)